Talawar Therapeutics announced a $225 million private investment in public equity (PIPE) alongside a business combination with JATT II Acquisition Corp, expected to close in the second half of 2026. The funding will support the development of TALA-125, a novel bispecific antibody targeting atopic dermatitis, through a Phase 2b proof-of-concept study with data expected in late 2028. TALA-125 aims to improve treatment efficacy by combining two validated immune pathways in one therapy. The combined company will trade on Nasdaq under the ticker TLWR, led by experienced biotech executives, and plans clinical entry for TALA-125 in early 2027 with interim Phase 1 data by the end of 2027.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
